Raptor Pharmaceuticals
Engages in the discovery, research, and preclinical development of drug candidates and drug-targeting platforms for the treatment of various brain disorders and neurodegenerative diseases, genetic disorders, and cancer through the proprietary use of .
Launch date
Market cap
-
Enterprise valuation
AUD93—139m (Dealroom.co estimates Aug 2010.)
Novato California (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
N/A | $2.4m | Early VC | |
$15.0m | Early VC | ||
* | $50.0m | Post IPO Debt | |
N/A | $10.0m | Debt | |
$60.0m | Post IPO Debt | ||
* | N/A | $85.5m | Post IPO Equity |
$800m | Acquisition | ||
Total Funding | AUD26.9m |